Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Xenon Pharmaceuticals Inc. (XENE) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Xenon Pharmaceuticals Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1582313.
Total stock buying since 2015: $2,648,532.
Total stock sales since 2015: $27,331,384.
Total stock option exercises since 2015: $7,447,950.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 55,000 | $2,218,270 | 60,144 | $1,041,458 |
| 2024 | 0 | $0 | 32,829 | $1,397,409 | 44,061 | $485,023 |
| 2023 | 0 | $0 | 226,810 | $8,872,923 | 294,231 | $2,836,914 |
| 2022 | 700 | $20,167 | 366,712 | $12,999,914 | 175,913 | $941,506 |
| 2021 | 4,000 | $97,600 | 28,621 | $756,790 | 116,666 | $408,884 |
| 2020 | 0 | $0 | 8,000 | $113,240 | 38,063 | $138,381 |
| 2019 | 0 | $0 | 32,661 | $306,184 | 130,653 | $437,632 |
| 2018 | 0 | $0 | 0 | $0 | 83,329 | $301,148 |
| 2017 | 714,015 | $2,497,905 | 0 | $0 | 63,783 | $227,994 |
| 2016 | 5,300 | $32,860 | 60,000 | $469,992 | 61,211 | $198,553 |
| 2015 | 0 | $0 | 22,149 | $196,662 | 95,504 | $430,457 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 0 | $0 | 0 | $0 | 5,144 | $64,660 |
| 2025-01 | 0 | $0 | 55,000 | $2,218,270 | 55,000 | $976,798 |
| 2024-12 | 0 | $0 | 18,709 | $770,997 | 25,334 | $266,260 |
| 2024-11 | 0 | $0 | 4,891 | $200,922 | 6,586 | $68,691 |
| 2024-03 | 0 | $0 | 9,229 | $425,490 | 12,141 | $150,072 |
| 2023-12 | 0 | $0 | 18,978 | $754,052 | 18,722 | $180,335 |
| 2023-08 | 0 | $0 | 25,000 | $967,500 | 0 | $0 |
| 2023-06 | 0 | $0 | 31,713 | $1,232,842 | 54,318 | $691,196 |
| 2023-05 | 0 | $0 | 131,187 | $5,182,919 | 149,175 | $1,775,621 |
| 2023-03 | 0 | $0 | 19,932 | $735,610 | 72,016 | $189,762 |
| 2022-12 | 0 | $0 | 0 | $0 | 3,086 | $8,270 |
| 2022-11 | 0 | $0 | 3,994 | $138,000 | 2,057 | $5,512 |
| 2022-08 | 0 | $0 | 234,878 | $9,019,749 | 65,000 | $255,125 |
| 2022-03 | 0 | $0 | 127,840 | $3,842,165 | 105,770 | $672,599 |
| 2022-01 | 700 | $20,167 | 0 | $0 | 0 | $0 |
| 2021-12 | 4,000 | $97,600 | 0 | $0 | 5,143 | $18,874 |
| 2021-11 | 0 | $0 | 17,557 | $550,060 | 0 | $0 |
| 2021-05 | 0 | $0 | 11,064 | $206,730 | 65,227 | $245,568 |
| 2021-02 | 0 | $0 | 0 | $0 | 46,296 | $144,442 |
| 2020-12 | 0 | $0 | 0 | $0 | 3,086 | $11,603 |
| 2020-10 | 0 | $0 | 0 | $0 | 12,345 | $46,416 |
| 2020-06 | 0 | $0 | 3,000 | $43,290 | 13,374 | $47,404 |
| 2020-05 | 0 | $0 | 5,000 | $69,950 | 9,258 | $32,958 |
| 2019-12 | 0 | $0 | 0 | $0 | 5,143 | $18,308 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-14 | Gannon Steven | Option Ex | 5,144 | 12.57 | 64,660 |
| 2025-01-27 | Mortimer Ian (PRESIDENT & CEO) | Sale | 16,315 | 40.77 | 665,080 |
| 2025-01-27 | Mortimer Ian (PRESIDENT & CEO) | Option Ex | 16,315 | 17.76 | 289,754 |
| 2025-01-24 | Mortimer Ian (PRESIDENT & CEO) | Sale | 22,468 | 40.20 | 903,213 |
| 2025-01-24 | Mortimer Ian (PRESIDENT & CEO) | Option Ex | 22,468 | 17.76 | 399,031 |
| 2025-01-23 | Mortimer Ian (PRESIDENT & CEO) | Sale | 16,217 | 40.08 | 649,977 |
| 2025-01-23 | Mortimer Ian (PRESIDENT & CEO) | Option Ex | 16,217 | 17.76 | 288,013 |
| 2024-12-18 | Aulin Sherry (Chief Financial Officer) | Sale | 18,709 | 41.21 | 770,997 |
| 2024-12-18 | Aulin Sherry (Chief Financial Officer) | Option Ex | 25,334 | 10.51 | 266,260 |
| 2024-11-22 | Patou Gary | Sale | 4,891 | 41.08 | 200,922 |
| 2024-11-22 | Patou Gary | Option Ex | 6,586 | 10.43 | 68,691 |
| 2024-03-08 | Garofalo Elizabeth A. | Sale | 2,092 | 45.69 | 95,583 |
| 2024-03-08 | Garofalo Elizabeth A. | Option Ex | 3,500 | 18.56 | 64,959 |
| 2024-03-07 | Robin Sherrington (EVP, Strategy & Innovation) | Sale | 7,137 | 46.23 | 329,907 |
| 2024-03-07 | Robin Sherrington (EVP, Strategy & Innovation) | Option Ex | 8,641 | 9.85 | 85,113 |
| 2023-12-19 | Azab Mohammad | Option Ex | 4,320 | 9.85 | 42,552 |
| 2023-12-13 | Patou Gary | Sale | 18,978 | 39.73 | 754,052 |
| 2023-12-13 | Patou Gary | Option Ex | 14,402 | 9.57 | 137,783 |
| 2023-08-24 | Svoronos Dawn | Sale | 25,000 | 38.70 | 967,500 |
| 2023-06-01 | Pimstone Simon N. | Sale | 31,713 | 38.88 | 1,232,842 |
| 2023-06-01 | Pimstone Simon N. | Option Ex | 54,318 | 12.72 | 691,196 |
| 2023-05-31 | Pimstone Simon N. | Sale | 62,526 | 38.68 | 2,418,318 |
| 2023-05-31 | Pimstone Simon N. | Option Ex | 79,835 | 13.80 | 1,102,122 |
| 2023-05-30 | Pimstone Simon N. | Sale | 37,006 | 39.27 | 1,453,040 |
| 2023-05-24 | Mortimer Ian (PRESIDENT & CEO) | Sale | 31,655 | 41.43 | 1,311,561 |
| 2023-05-24 | Mortimer Ian (PRESIDENT & CEO) | Option Ex | 69,340 | 9.71 | 673,499 |
| 2023-03-24 | Kenney Christopher John (Chief Medical Officer) | Sale | 700 | 35.01 | 24,507 |
| 2023-03-07 | Pimstone Simon N. (Director) | Sale | 19,232 | 36.98 | 711,103 |
| 2023-03-07 | Pimstone Simon N. (Director) | Option Ex | 72,016 | 2.63 | 189,762 |
| 2022-12-12 | Azab Mohammad (Director) | Option Ex | 3,086 | 2.68 | 8,270 |
| 2022-11-25 | Patou Gary (Director) | Sale | 1,937 | 34.79 | 67,390 |
| 2022-11-25 | Patou Gary (Director) | Option Ex | 2,057 | 2.68 | 5,512 |
| 2022-11-23 | Patou Gary (Director) | Sale | 2,057 | 34.33 | 70,610 |
| 2022-08-16 | Pimstone Simon N. (Director) | Sale | 52,058 | 38.58 | 2,008,397 |
| 2022-08-15 | Pimstone Simon N. (Director) | Sale | 33,942 | 37.76 | 1,281,649 |
| 2022-08-12 | Empfield James R. (EVP, Drug Discovery) | Sale | 57,743 | 38.38 | 2,216,176 |
| 2022-08-12 | Empfield James R. (EVP, Drug Discovery) | Option Ex | 65,000 | 3.92 | 255,125 |
| 2022-08-12 | Pimstone Simon N. (Director) | Sale | 91,135 | 38.55 | 3,513,527 |
| 2022-03-08 | Pimstone Simon N. (Director) | Sale | 14,551 | 25.96 | 377,714 |
| 2022-03-07 | Empfield James R. (EVP, Drug Discovery) | Sale | 32,853 | 30.58 | 1,004,644 |
| 2022-03-07 | Empfield James R. (EVP, Drug Discovery) | Option Ex | 42,500 | 7.58 | 322,150 |
| 2022-03-07 | Pimstone Simon N. (Director) | Sale | 31,086 | 30.51 | 948,340 |
| 2022-03-07 | Pimstone Simon N. (Director) | Option Ex | 20,576 | 3.67 | 75,513 |
| 2022-03-04 | Empfield James R. (EVP, Drug Discovery) | Sale | 18,315 | 30.79 | 563,918 |
| 2022-03-04 | Empfield James R. (EVP, Drug Discovery) | Option Ex | 25,000 | 8.40 | 210,000 |
| 2022-03-04 | Pimstone Simon N. (Director) | Sale | 9,325 | 30.61 | 285,438 |
| 2022-03-04 | Pimstone Simon N. (Director) | Option Ex | 10,288 | 3.67 | 37,756 |
| 2022-03-04 | Robin Sherrington (EVP, Strategy & Innovation) | Sale | 21,710 | 30.50 | 662,111 |
| 2022-03-04 | Robin Sherrington (EVP, Strategy & Innovation) | Option Ex | 7,406 | 3.67 | 27,180 |
| 2022-01-21 | Kenney Christopher John (Chief Medical Officer) | Buy | 700 | 28.81 | 20,167 |
| 2021-12-15 | Azab Mohammad (Director) | Option Ex | 3,086 | 3.67 | 11,325 |
| 2021-12-08 | Patou Gary (Director) | Option Ex | 2,057 | 3.67 | 7,549 |
| 2021-12-06 | Von Seggern Christopher (Chief Commercial Officer) | Buy | 4,000 | 24.40 | 97,600 |
| 2021-11-15 | Pimstone Simon N. (Director) | Sale | 17,557 | 31.33 | 550,060 |
| 2021-05-27 | Holler Frank A (Director) | Sale | 11,064 | 18.68 | 206,730 |
| 2021-05-27 | Holler Frank A (Director) | Option Ex | 39,094 | 3.76 | 146,993 |
| 2021-05-24 | Pimstone Simon N. (CEO) | Option Ex | 22,633 | 3.76 | 85,100 |
| 2021-05-18 | Hayden Michael R (Director) | Option Ex | 3,500 | 3.85 | 13,475 |
| 2021-02-18 | Hayden Michael R (Director) | Option Ex | 41,152 | 3.17 | 130,657 |
| 2021-02-16 | Hayden Michael R (Director) | Option Ex | 5,144 | 2.68 | 13,785 |
| 2020-12-15 | Azab Mohammad (Director) | Option Ex | 3,086 | 3.76 | 11,603 |
| 2020-10-28 | Patou Gary (Director) | Option Ex | 2,057 | 3.76 | 7,734 |
| 2020-10-28 | Tarnow Michael M (Director) | Option Ex | 10,288 | 3.76 | 38,682 |
| 2020-06-09 | Tarnow Michael M (Director) | Option Ex | 5,144 | 3.52 | 18,106 |
| 2020-06-01 | Pimstone Simon N. (CEO) | Sale | 3,000 | 14.43 | 43,290 |
| 2020-06-01 | Robin Sherrington (EVP, Strategy & Innovation) | Option Ex | 8,230 | 3.56 | 29,298 |
| 2020-05-29 | Pimstone Simon N. (CEO) | Sale | 5,000 | 13.99 | 69,950 |
| 2020-05-29 | Holler Frank A (Director) | Option Ex | 3,086 | 3.56 | 10,986 |
| 2020-05-26 | Pimstone Simon N. (CEO) | Option Ex | 6,172 | 3.56 | 21,972 |
| 2019-12-16 | Azab Mohammad (Director) | Option Ex | 3,086 | 3.56 | 10,986 |
| 2019-12-04 | Patou Gary (Director) | Option Ex | 2,057 | 3.56 | 7,322 |
| 2019-11-21 | Tarnow Michael M (Director) | Option Ex | 7,201 | 3.54 | 25,455 |
| 2019-09-20 | Pimstone Simon N. (CEO) | Sale | 10,395 | 9.51 | 98,856 |
| 2019-09-20 | Holler Frank A (Director) | Sale | 5,206 | 9.39 | 48,884 |
| 2019-09-19 | Holler Frank A (Director) | Sale | 7,600 | 9.27 | 70,452 |
| 2019-09-18 | Holler Frank A (Director) | Sale | 4,368 | 9.28 | 40,535 |
| 2019-09-17 | Pimstone Simon N. (CEO) | Option Ex | 57,612 | 3.38 | 194,901 |
| 2019-09-17 | Holler Frank A (Director) | Sale | 5,069 | 9.32 | 47,243 |
| 2019-09-13 | Azab Mohammad (Director) | Sale | 23 | 9.31 | 214 |
| 2019-09-12 | Robin Sherrington (EVP, Strategy & Innovation) | Option Ex | 6,172 | 3.07 | 18,948 |
| 2019-09-12 | Holler Frank A (Director) | Option Ex | 31,892 | 3.26 | 103,872 |
| 2019-05-21 | Tarnow Michael M (Director) | Option Ex | 2,057 | 3.21 | 6,602 |
| 2019-03-19 | Hayden Michael R (Director) | Option Ex | 20,576 | 3.38 | 69,546 |
| 2018-12-14 | Patou Gary | Option Ex | 2,057 | 3.07 | 6,314 |
| 2018-12-11 | Cohen Charles J. (VP, Biology) | Option Ex | 4,115 | 3.07 | 12,633 |
| 2018-12-06 | Azab Mohammad (Director) | Option Ex | 3,086 | 3.07 | 9,474 |
| 2018-06-21 | Azab Mohammad | Option Ex | 10,288 | 3.70 | 38,065 |
| 2018-06-21 | Tarnow Michael M | Option Ex | 12,345 | 3.48 | 42,923 |
| 2018-06-14 | Patou Gary | Option Ex | 8,230 | 3.70 | 30,451 |
| 2018-03-15 | Robin Sherrington (EVP Bus. & Corp. Development) | Option Ex | 3,086 | 3.77 | 11,634 |
| 2018-03-14 | Holler Frank A | Option Ex | 3,086 | 3.77 | 11,634 |
| 2018-03-12 | Pimstone Simon N. (CEO) | Option Ex | 10,288 | 3.77 | 38,785 |
| 2018-02-12 | Cohen Charles J. (VP, Biology) | Option Ex | 26,748 | 3.71 | 99,235 |
| 2017-11-15 | Azab Mohammad | Buy | 15,000 | 2.22 | 33,285 |
| 2017-09-22 | Azab Mohammad | Buy | 8,000 | 2.95 | 23,600 |
| 2017-09-21 | Azab Mohammad | Buy | 2,000 | 2.95 | 5,900 |
| 2017-08-18 | Winquist Raymond (Head, Translational Research) | Buy | 1,000 | 3.00 | 2,995 |
| 2017-08-18 | Azab Mohammad | Buy | 6,312 | 2.90 | 18,304 |
| 2017-08-17 | Azab Mohammad | Buy | 23 | 2.65 | 60 |
| 2017-08-15 | Empfield James R. (SVP, Drug Discovery) | Buy | 10,000 | 2.48 | 24,820 |
| 2017-08-15 | Lampert Mark N | Buy | 18,858 | 2.41 | 45,485 |
| 2017-08-14 | Svoronos Dawn | Buy | 50,000 | 2.81 | 140,750 |
| 2017-08-14 | Hayden Michael R | Buy | 15,000 | 2.75 | 41,250 |
| 2017-08-14 | Lampert Mark N | Buy | 41,344 | 2.70 | 111,794 |
| 2017-08-11 | Gannon Steven | Buy | 15,000 | 2.82 | 42,270 |
| 2017-08-10 | Pimstone Simon N. (President & CEO) | Buy | 6,000 | 2.90 | 17,400 |
| 2017-08-10 | Mortimer Ian (CFO & COO) | Buy | 15,000 | 2.87 | 43,095 |
| 2017-08-10 | Patou Gary | Buy | 7,500 | 2.78 | 20,835 |
| 2017-08-10 | Scheller Richard H | Buy | 7,000 | 2.85 | 19,950 |
| 2017-08-08 | Patou Gary | Buy | 5,000 | 3.00 | 15,005 |
| 2017-06-27 | Lampert Mark N | Buy | 85,461 | 4.00 | 341,844 |
| 2017-06-22 | Lampert Mark N | Buy | 8,263 | 4.00 | 33,052 |
| 2017-06-21 | Lampert Mark N | Buy | 12,148 | 4.00 | 48,592 |
| 2017-06-19 | Tarnow Michael M | Option Ex | 1,028 | 3.51 | 3,608 |
| 2017-06-19 | Lampert Mark N | Buy | 3,595 | 3.85 | 13,840 |
| 2017-06-16 | Lampert Mark N | Buy | 11,034 | 3.85 | 42,480 |
| 2017-06-15 | Lampert Mark N | Buy | 11,779 | 3.84 | 45,196 |
| 2017-06-07 | Lampert Mark N | Buy | 207,789 | 3.85 | 800,195 |
| 2017-06-06 | Lampert Mark N | Buy | 150,909 | 3.75 | 565,908 |
| 2017-05-12 | Robin Sherrington (SVP Bus. & Corp. Development) | Option Ex | 2,057 | 3.21 | 6,602 |
| 2017-03-14 | Hayden Michael R | Option Ex | 60,698 | 3.59 | 217,784 |
| 2016-12-15 | Holler Frank A | Sale | 30,000 | 7.85 | 235,500 |
| 2016-12-12 | Tarnow Michael M | Option Ex | 14,403 | 3.21 | 46,233 |
| 2016-12-06 | Patou Gary | Option Ex | 12,345 | 3.21 | 39,627 |
| 2016-12-01 | Azab Mohammad | Option Ex | 12,345 | 3.21 | 39,627 |
| 2016-08-19 | Holler Frank A | Sale | 11,938 | 7.65 | 91,337 |
| 2016-08-18 | Holler Frank A | Sale | 9,599 | 7.70 | 73,912 |
| 2016-08-17 | Holler Frank A | Sale | 1,600 | 7.89 | 12,624 |
| 2016-08-16 | Holler Frank A | Sale | 6,863 | 8.25 | 56,619 |
| 2016-07-29 | Pimstone Simon N. (President & CEO) | Option Ex | 12,345 | 3.30 | 40,738 |
| 2016-06-24 | Mortimer Ian (CFO & COO) | Buy | 5,300 | 6.20 | 32,860 |
| 2016-05-25 | Hayden Michael R | Option Ex | 8,230 | 3.30 | 27,159 |
| 2016-04-28 | Tarnow Michael M | Option Ex | 1,543 | 3.35 | 5,169 |
| 2015-12-16 | Robin Sherrington (SVP Bus. & Corp. Development) | Option Ex | 411 | 5.22 | 2,145 |
| 2015-12-11 | Azab Mohammad | Option Ex | 2,469 | 5.22 | 12,888 |
| 2015-11-24 | Holler Frank A | Option Ex | 2,057 | 5.22 | 10,737 |
| 2015-11-04 | Patou Gary | Option Ex | 3,497 | 5.22 | 18,254 |
| 2015-11-02 | Tarnow Michael M | Option Ex | 5,041 | 5.22 | 26,314 |
| 2015-09-24 | Goldberg Y. Paul (VP of Clinical Development) | Sale | 12,000 | 8.60 | 103,200 |
| 2015-09-23 | Goldberg Y. Paul (VP of Clinical Development) | Sale | 4,000 | 9.02 | 36,080 |
| 2015-09-22 | Goldberg Y. Paul (VP of Clinical Development) | Sale | 6,149 | 9.33 | 57,382 |
| 2015-09-22 | Goldberg Y. Paul (VP of Clinical Development) | Option Ex | 30,388 | 3.49 | 106,145 |
| 2015-08-18 | Pimstone Simon N. (President & CEO) | Option Ex | 20,576 | 4.89 | 100,719 |
| 2015-08-18 | Robin Sherrington (SVP Bus. & Corp. Development) | Option Ex | 3,085 | 4.89 | 15,101 |
| 2015-08-18 | Goldberg Y. Paul (VP of Clinical Development) | Option Ex | 3,085 | 4.89 | 15,101 |
| 2015-08-18 | Holler Frank A | Option Ex | 2,057 | 4.98 | 10,243 |
| 2015-06-17 | Tarnow Michael M | Option Ex | 1,543 | 4.95 | 7,637 |
| 2015-02-03 | Hayden Michael R | Option Ex | 5,144 | 4.81 | 24,742 |
| 2015-01-08 | Hayden Michael R | Option Ex | 5,144 | 4.98 | 25,617 |
| 2015-01-08 | Azab Mohammad | Option Ex | 2,469 | 4.98 | 12,295 |
| 2015-01-08 | Tarnow Michael M | Option Ex | 5,041 | 4.98 | 25,104 |
| 2015-01-07 | Patou Gary | Option Ex | 3,497 | 4.98 | 17,415 |
Insider trading activities including stock purchases, stock sales, and option exercises of XENE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Xenon Pharmaceuticals Inc. (symbol XENE, CIK number 1582313) see the Securities and Exchange Commission (SEC) website.